Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Chung Yin Kong"'
Autor:
Chung Yin Kong, G. Scott Gazelle, Sylvia K. Plevritis, Rafael Meza, Koen de Nijs, Harry J. de Koning, Mehrad Bastani, Jihyoun Jeon, Pianpian Cao, Iakovos Toumazis, Vidit Munshi, Kevin ten Haaf, Eric J. Feuer, Summer S. Han
Publikováno v:
JAMA Oncology, 7(12), 1833-1842. American Medical Association
JAMA Oncol
JAMA Oncol
Importance The US Preventive Services Task Force (USPSTF) issued its 2021 recommendation on lung cancer screening, which lowered the starting age for screening from 55 to 50 years and the minimum cumulative smoking exposure from 30 to 20 pack-years r
Publikováno v:
Radiology. 300:586-593
Background Guidelines such as the Lung CT Screening Reporting and Data System (Lung-RADS) are available for determining when subsolid nodules should be treated within lung cancer screening programs, but they are based on expert opinion. Purpose To ev
Autor:
Christopher J, Cadham, Pianpian, Cao, Jinani, Jayasekera, Kathryn L, Taylor, David T, Levy, Jihyoun, Jeon, Elena B, Elkin, Kristie L, Foley, Anne, Joseph, Chung Yin, Kong, Jennifer A, Minnix, Nancy A, Rigotti, Benjamin A, Toll, Steven B, Zeliadt, Rafael, Meza, Jeanne, Mandelblatt
Publikováno v:
JNCI: Journal of the National Cancer Institute. 113:1065-1073
Background Guidelines recommend offering cessation interventions to smokers eligible for lung cancer screening, but there is little data comparing specific cessation approaches in this setting. We compared the benefits and costs of different smoking
Autor:
Iakovos Toumazis, Erik F. Blom, Jihyoun Jeon, Kevin ten Haaf, Pianpian Cao, Deirdre F. Sheehan, Yufan Chen, Rafael Meza, Steven D. Criss, Sylvia K. Plevritis, Mehrad Bastani, Harry J. de Koning, Chung Yin Kong
Publikováno v:
Annals of Internal Medicine, 171:WOS:000506426000005, 796-804. American College of Physicians
Background Recommendations vary regarding the maximum age at which to stop lung cancer screening: 80 years according to the U.S. Preventive Services Task Force (USPSTF), 77 years according to the Centers for Medicare & Medicaid Services (CMS), and 74
Autor:
Mark M. Hammer, Chung Yin Kong
Publikováno v:
AJR. American journal of roentgenology. 218(4)
Please see the Editorial Comment by Kathryn P. Lowry discussing this article. Background: Thyroid nodules are common incidental findings on CT. Existing professional society recommendations, based ...
Autor:
Shuhei Nomura, Eiko Saito, Kota Katanoda, Chi Yan Leung, Chin Hur, Chung Yin Kong, Hsi-Lan Huang, Kenji Shibuya
Publikováno v:
BMC Medicine
BMC Medicine, Vol 18, Iss 1, Pp 1-12 (2020)
BMC Medicine, Vol 18, Iss 1, Pp 1-12 (2020)
BackgroundA national endoscopic screening program for gastric cancer was rolled out in Japan in 2015. We used a microsimulation model to estimate the cost-effectiveness of current screening guidelines and alternative screening strategies in Japan.Met
Autor:
Andrew Eckel, Lauren Palazzo, Eduardo J. Mortani Barbosa, Francine L. Jacobson, Adelle M. Paquette, Mark M. Hammer, Chung Yin Kong
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 15(8)
Objective To evaluate the cost-effectiveness of a number of follow-up guidelines and variants for subsolid pulmonary nodules. Methods We used a simulation model informed by data from the literature and the National Lung Screening Trial to simulate pa
Autor:
Tina R. Watson, Meghan J. Mooradian, Justin F. Gainor, Kerry L. Reynolds, Steven D. Criss, Chung Yin Kong
Publikováno v:
JAMA Network Open
Key Points Question Is atezolizumab plus bevacizumab, carboplatin, and paclitaxel (atezolizumab combination) cost-effective as a first-line treatment strategy for US patients with metastatic nonsquamous non–small cell lung cancer? Findings In this
Publikováno v:
Radiol Cardiothorac Imaging
To evaluate nodule management guidelines in a simulated cohort of Lung Reporting and Data System (Lung-RADS) 4 nodules based on real-world data.In this retrospective study, 100 000 patients were simulated from 151 patients with Lung-RADS 4 nodules (f
Publikováno v:
JAMA Network Open
This economic evaluation compares the cost-effectiveness of pembrolizumab-axitinib vs nivolumab-ipilimumab for treatment of advanced renal cell carcinoma (ARCC) in the US.
Key Points Question Is pembrolizumab-axitinib cost-effective as first-lin
Key Points Question Is pembrolizumab-axitinib cost-effective as first-lin